Exton

EXTON, Pennsylvania, December 12, 2011 - Clinicians and carers of children and adolescents suffering from prolonged, acute, convulsive seizures now have access to Buccolam (midazolam oromucosal solution), a newly approved rescue medication to treat prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years of age.[1] For infants between three to six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

EXTON, Pennsylvania, November 15, 2011 - - Completion Follows European Marketing Authorization and Confirmation of Orphan Drug Designation for Plenadren (Hydrocortisone, Modified Release Tablet) - ViroPharma Incorporated (NASDAQ: VPHM) today announced that it completed its acquisition of DuoCort Pharma AB, a private company based in Helsingborg, Sweden focused on improving glucocorticoid replacement therapy.

EXTON, Pennsylvania, October 27, 2011 - - Positive CHMP Opinion Adopted for Product to Treat Adrenal Insufficiency, an Orphan Disease with Limited Treatment Options - ViroPharma Incorporated (NASDAQ: VPHM) today announced that it has signed a definitive agreement to acquire DuoCort Pharma AB, a private company based in Helsingborg, Sweden focused on improving glucocorticoid replacement therapy.

EXTON, Pennsylvania, September 6, 2011 - - Approval Offers Convenient Alternative to Treat Seizures in Children and Adolescents - - First Ever Product Approved through European Commission's Centralized Pediatric Use Marketing Authorization (PUMA) - ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted a Centralized Pediatric Use Marketing Authorization (PUMA) for Buccolam (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years of age.

EXTON, Pennsylvania, June 24, 2011 - ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.